Clinical Trial Update: Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating the combination of erlotinib and bevacizumab in chemotherapy-naïve non-small cell lung cancer patients with performance status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Nasser Hanna, M.D. | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-02-11